Taisho Pharmaceutical Holdings Co., Ltd.
TAISF
Other OTC59.00
USD
-0.23
- -
ISIN
JP3442850008
Return %
Stock
S&P500
1Y
55.26
18.99
3Y
-12.11
64.75
5Y
-12.11
71.84
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Akira Uehara
- Full Time Employees
- 8,784
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 3-24-1 Takada Tokyo Japan 170-8655
- IPO Date
- Jun 26, 2023
- Website
- taisho-holdings.co.jp
- Similar Companies
- Business
- Taisho Pharmaceutical Holdings Co., Ltd. serves as the holding company for the Taisho Pharmaceutical Group, which researches, develops, manufactures, markets and sells over-the-counter (OTC) drugs, quasi-drugs, prescription pharmaceuticals, health foods, skin care products and general medical supplies primarily in Japan, Southeast Asia and Europe. The group's core OTC portfolio encompasses more than 40 brands, including the Lipovitan series of energy drinks; Pabron series of cough, cold and sinus remedies; RiUP series of hair re-growth treatments; Taisho Kampo series of gastrointestinal products; Colac series of laxatives; Naron series of antipyretic analgesics; Preser series of hemorrhoid treatments; Vicks cough suppressants; Counterpain topical anti-inflammatories; and others such as Hapacol, Efferalgan, Dafalgan, Tempra, Vitacilina and UPSA; while its prescription offerings feature Clarith macrolide antibiotic, Bonviva bisphosphonate for osteoporosis, Lusefi SGLT2 inhibitor for type 2 diabetes and LOQOA transdermal anti-inflammatory analgesic. Taisho Pharmaceutical Holdings operates subsidiaries including Taisho Pharmaceutical Co., Ltd., Biofermin Pharmaceutical, Duoc Hau Giang Pharmaceutical JSC in Vietnam, HOE Pharmaceuticals in Malaysia and UPSA in France, with geographic focus on Japan, Asia-Pacific markets, and European expansion. Founded in 1912 and headquartered in Toshima-ku, Tokyo, Japan, the company traces its origins to Taisho Seiyakusho, evolving into a leader in Japan's OTC market through iconic brands like Lipovitan D, launched in 1962, and expanding into prescription drugs from the 1950s. Among recent developments, Taisho Pharmaceutical announces a strategic collaboration and exclusive license agreement with Biolinq for Japan in 2024; participates in LTZ Therapeutics' $40 million Series A funding round in April 2025; completes a management buyout via tender offer from Otemon Co., Ltd., leading to delisting from the Tokyo Stock Exchange on April 9, 2024; launches alli, Japan's first direct-to-OTC visceral fat reducing drug, and Nanozora anti-TNFα nanobody preparation with auto-injector; and consolidates Duoc Hau Giang as a full subsidiary following prior equity affiliation.